Pipeline

MFA011 enables targeted delivery of IL-15 to tumor-associated immune cells, maximizing immune activation where it is needed most, by combining our proprietary anti-TIGIT antibody with an engineered IL-15 cytokine. This approach enhances the proliferation and function of NK cells and CD8+ T cells while minimizing systemic cytokine exposure. In preclinical studies, MFA011 demonstrated potent anti-tumor activity, durable immune activation, and a favorable safety profile.

Key Features

• Enhanced activation of NK cells and T cells through IL-15 signaling
• Improved PK and half-life compared to conventional immunocytokine therapies
• Expanded therapeutic window with reduced systemic toxicity
• Potent anti-tumor efficacy with favorable in vivo safety